[1] VOGESER M， HAAS A， AUAT D， et al. Postmortem analysis of invasive aspergillosis in a tertiary care hospital[J] . Eur J Clin Microbiol Infect Dis，1997，16：1-6. [2] DENNING D W. Invasive aspergillosis[J] . Clin Infect Dis，1998，26：781-805. [3] MOORE R D， CHAISSON R E. Natural history of opportunistic disease in an HIV-infected nrban clinical cohort[J] . Ann Intern Med，1996，124：633-642. [4] SANGLARD D， ODDS F C. Resistance of Candida species to antifungal agents： molecular mechanisms and clinical consequences[J] . Lancet Infect Dis，2002，2：73-85. [5] DOUGLAS C. Fundal beta (1，3)-D-glucan synthesis[J] . Med Mycol，2001，39(Supple 1)：55-66. [6] POPOLO L， GUALTIERI T，RAGNI E. The yeast cell-wall salvage pathway[J] . Med Mycol，2001，39：(Supple 1)：111-121. [7] OSHEROV N，MAY G S， ALBERT N D，et al. Overexpression of Sbe2p， a Golgi protein， results in resistance to caspofungin in Saccharomyces cerevisiae[J] . Antimicrob Agents Chemother，2002，46：2462-2469. [8] STONE J A， HOLLAND S D， WICKERSHAM P J，et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men[J] . Antimicrob Agents Chemother，2002，46：739-745. [9] MIKAMO H， SATO Y， TAMAYA T. In vitro antifungal activity of FK463， a new water-soluble echinocandin-like lipopeptide[J] . J Antimicrob Chemother，2000，46：485-487. [10] MOORE C B， OAKLEY K L， DENNING D W. In vitro activity of a new echinocandin，LY303366，and comparison with fluconazole， flucytosine and amphotericin B against Candida species[J] . Clin Microbiol Infect，2001，7：11-16. [11] RATHOON E G， GOTUZZO E， Noriega L N M，et al. Randomized， double-blind， multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases[J] . Antimicrob Agents Chemother，2002，46：451-457. [12] KARTSONIS N， DINUBILE M J， BARTIZAL K，et al. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole[J] . J Acquir Immune Defic Syndr，2002，31：183-187. [13] MORA-DUARTE， BETTS R， ROTSTEIN C，et al. Comparison of caspofungin and amphotericin B for invasive candidiasis[J] . N Engl J Med，2002，347：2020-2029. [14] ARIKAN S， LOZANO-CHIU M， Paetznick V，et al. In vitro synergy of caspofungin and amphotericin B against aspergillus and fusarium spp[J] . Antimicrob Agents Chemother，2002,46：245-247. [15] CHIOU C C， MAVROGIORGOS N， TILLEM E，et al. Synergy， pharmacodynamics， and time-sequenced ultrastructural changes of the interaction betweennikkomycin Z and the echinocandin FK463 against aspergillus fumigatus[J] . Antimicrob Agents Chemother，2001，45：3310-3321. [16] KIRKPATRICK W R， PEREA S，COCO B J，et al. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis[J] . Antimicrob Agents Chemother，2002，46：2564-2568. [17] WARN P A， MORRISSEY G， MORRISSEY J，et al. Activity of FK463 against an itraconazole resistant strain of Aspergillus fumigatus and amphotericin B resistant aspergillus terrus[J] . J Antimicrob Chemother，2003，51：913-919. [18] STEINBACH W J， STEVENS D A， DENING D W. Combination and sequential antifungal therapy for invasive aspergillosis： review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2002[J] . Clin Infect Dis，2003，37(supple)：S188-224. [19] ROLING E E， KLEPSER M E， WASSON A，et al. Antifungal activities of fluconzale， caspofungin(MK099)， and anidulafungin (LY303366) alone and in combination against candida spp and crytococcus neoformans via time-kill methods[J] . Diagn Microbiol Infect Dis，2002，43：13-17.